A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial

H. R. Keir, M. B. Long, H. Abo leyah, Y. H. Giam, T. Vadiveloo, T. Pembridge, R. Hull, L. Delgado, M. Band, F. Mclaren-Neill, S. Adamson, E. Lahnsteiner, A. Gilmour, C. Hughes, B. J. M. New, D. Connell, R. Dowey, H. Turton, H. Richardson, D. CassidyJ. Cooper, J. Suntharalingam, L. Diwakar, P. Russell, J. Underwood, A. Hicks, D. P. Dosanjh, E. Sage, D. Dhasmana, M. Spears, R. Thompson, C. Brightling, M. Patel, J. George, A. M. Condliffe, A. Shoemark, G. Maclennan, J. D. Chalmers

Research output: Contribution to conferencePaperpeer-review

Abstract

Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count
Original languageEnglish
PagesA5055-A5055
Number of pages1
DOIs
Publication statusPublished - 2 May 2022
EventAmerican Thoracic Society International Conference 2022 - San Francisco, United States
Duration: 13 May 202218 May 2022
http://American Thoracic Society International Conference

Conference

ConferenceAmerican Thoracic Society International Conference 2022
Country/TerritoryUnited States
CitySan Francisco
Period13/05/2218/05/22
Internet address

Fingerprint

Dive into the research topics of 'A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial'. Together they form a unique fingerprint.

Cite this